COMMUNIQUÉS West-GlobeNewswire

INNATE PHARMA: nouvelles données précliniques renforçant le rationnel d'IPH5401 et monalizumab

11/09/2017 - 07:00

ConfÉrence ICI 2017 : NOUVELLES donnÉes prÉcliniques RENFORcant le rationnel d'iph5401 et monalizumab dans le traitement du cancer et en combinaison avec des anti-PD-1/PD-L1 En inversant l'immunosuppression dans le [...]

First Patients Enrolled in UK's Early Access to Medicines Scheme for Santhera's Raxone® in Duchenne Muscular Dystrophy (DMD)

11/09/2017 - 07:00

Liestal, Switzerland, September 11, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces enrollment of first DMD patients with respiratory function decline not taking glucocorticoids into UK's Early Access to Medicines [...]

Targovax ASA: Three posters presented at ESMO conference

11/09/2017 - 07:00

Oslo, Norway, 11 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that three posters [...]

Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial

11/09/2017 - 06:58

Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma - Investigational dupilumab reduced severe asthma attacks and improved lung function - Paris, France [...]

Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé

11/09/2017 - 06:58

Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé - L'agent expérimental dupilumab a permis de réduire les [...]

Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

11/09/2017 - 00:05

The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified subgroups, including [...]

Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept

09/09/2017 - 11:00

Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal [...]

L'Association internationale pour l'étude du cancer du poumon annonce des sélections de rapports pour la 18e Conférence mondiale sur le cancer du poumon

08/09/2017 - 23:41

Des travaux de recherche révolutionnaires mettront en lumière les progrès les plus récents dans l'étude du cancer du poumon DENVER, 2017-09-08 (GLOBE NEWSWIRE) -- L'Association internationale pour l'étude du cancer du [...]

LifeVantage Corporation élargit sa présence mondiale avec une expansion en Allemagne

08/09/2017 - 18:18

Les produits disponibles en Allemagne incluent le Synergizer Nrf2 Protandim® et TrueScience®, la crème antivieillissement pour les soins de la peau de la société SALT LAKE CITY, le 8 septembre 2017 (GLOBE NEWSWIRE) - [...]

PCI Biotech: Capital increase registered and listing of new shares

08/09/2017 - 14:34

Oslo, 8 September 2017 - Reference is made to the stock exchange notice of 5 September 2017 by PCI Biotech Holding ASA (the "Company") in respect of the issuance of 86,500 new shares following exercise of employee share [...]

Information from Infant Bacterial Therapeutics Capital Markets Day 2017

08/09/2017 - 14:33

Infant Bacterial Therapeutics has today, September 8, 2017, hosted a Capital Markets Day for investors, financial analysts and media in Stockholm. The purpose of the Capital Markets Day was to present Infant Bacterial [...]

Inivata: Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer

08/09/2017 - 13:30

Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer Research Triangle Park, NC and Cambridge, UK, September 8, 2017 -- Inivata , a global clinical cancer genomics company utilizing an industry- [...]

Medtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon

08/09/2017 - 13:00

Clinically-Proven, Durable, Consistent, and Safe Market-Leading DCB Poised to Improve Outcomes for PAD Patients in Japan DUBLIN - September 8, 2017 - Medtronic plc (NYSE: MDT) today announced that the IN.PACT(TM)Admiral [...]

Nicox : Informations financières et point des activités du premier semestre 2017

08/09/2017 - 07:30

Communiqué de presse Nicox : Informations financières et point des activités du premier semestre 2017 Approbation de la demande d'autorisation de mise sur le marché ( New Drug Application , NDA) de ZERVIATE TM (solution [...]

Nicox first half 2017 business and financial update

08/09/2017 - 07:30

Press Release Nicox first half 2017 business and financial update ZERVIATE TM (cetirizine ophthalmic solution), 0.24% New Drug Application (NDA) approved Investigational New Drug (IND) submissions for NCX 470 for IOP [...]

Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma

08/09/2017 - 06:58

Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma Paris, France and Tarrytown, New York - September 8, 2017 - [...]

Sanofi et Regeneron annoncent que la FDA a accordé la désignation de « Découverte capitale » au cemiplimab (REGN2810) dans le traitement du carcinome épidermoïde cutané au stade avancé

08/09/2017 - 06:58

Sanofi et Regeneron annoncent que la FDA a accordé la désignation de « Découverte capitale » au cemiplimab (REGN2810) dans le traitement du carcinome épidermoïde cutané au stade avancé Paris (France) et Tarrytown (New [...]

Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies

07/09/2017 - 22:30

AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need Dedicated cardiovascular safety study [...]

LifeVantage Corporation Increases Global Footprint with Expansion into Germany

07/09/2017 - 22:05

Products available in Germany include Protandim® Nrf2 Synergizer and the company's TrueScience® Anti-Aging Skin Care Regimen SALT LAKE CITY, Sept. 07, 2017 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), [...]